AstraZeneca deepens UK-China ties with cell therapy R&D hub, manufacturing plansnews2026-03-19T15:29:18+00:00March 19th, 2026|Endpoints News|
Shanghai biotech Excalipoint gains $68.7M for T cell engagersnews2026-03-18T12:00:09+00:00March 18th, 2026|Endpoints News|
New renal disease biotech R1 Therapeutics nabs $77.5M for Phase 2bnews2026-03-17T11:00:34+00:00March 17th, 2026|Endpoints News|
China mRNA therapy startup Innorna to test gout treatment in USnews2026-03-17T11:00:08+00:00March 17th, 2026|Endpoints News|
Makary pushes for IRB reforms to catch China’s speedy trial startsnews2026-03-16T18:00:27+00:00March 16th, 2026|Endpoints News|
China startup CirCode gets clearance for trial of circular RNA therapynews2026-03-16T12:30:43+00:00March 16th, 2026|Endpoints News|
Lilly plots GLP-1 pill production boost in China, $500M pledge to South Koreanews2026-03-11T15:15:38+00:00March 11th, 2026|Endpoints News|
RA Capital, Forbion and Canaan appear to back Harbour’s CTLA-4 partner Solsticenews2026-03-11T11:00:40+00:00March 11th, 2026|Endpoints News|
Post-Hoc Live: What will the US government do about China biotech?news2026-03-06T13:35:00+00:00March 6th, 2026|Endpoints News|
Pfizer gets obesity drug approval in China shortly after buying local rightsnews2026-03-06T12:29:57+00:00March 6th, 2026|Endpoints News|
